Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma, Ewing 1Osteosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Colorectal Neoplasms 1

Interventions

Temozolomide 10Cyclophosphamide 10Vincristine 9Etoposide 6Doxorubicin 6Irinotecan 5palbociclib 4cabozantinib 4Topotecan 4Melphalan 4Magnetic Resonance Spectroscopy 4X-Rays 3Sirolimus 3Phantoms, Imaging 3Ifosfamide 3Gemcitabine 3ulixertinib 2tipifarnib 2tazemetostat 2selpercatinib 2olaparib 2ivosidenib 2irinotecan sucrosofate 2ganitumab 2cixutumumab 2Vemurafenib 2Trabectedin 2Tacrolimus 2Specimen Handling 2Peripheral Blood Stem Cell Transplantation 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Sarcoma, Ewing × robatumumab × Clear all
NCT00617890 2018-08-23

A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720)

Merck Sharp & Dohme LLC

Phase 2 Terminated
219 enrolled 13 charts
Sarcoma

Sarcoma, Ewing, Osteosarcoma, Neuroectodermal Tumors, Primitive, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡